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In 1970s, Heroin-associated Nephropathy (HAN), one form of focal and segmental
glomerulosclerosis (FSGS), was a predominant cause of End-stage Kidney Disease
(ESKD) in African-Americans (AAs). In 1980s, with the surge of Acquired Immune
Deficiency Syndrome (AIDS) in AAs, HAN more or less disappeared, and the incidence
of Human Immunodeficiency Virus associated Nephropathy (HIVAN) markedly increased.
Recent studies in AAs have identified APOL1 variants (Vs) as a major risk factor for the
development and progression of non-diabetic kidney diseases including idiopathic FSGS
and hypertension-attributed nephrosclerosis. These observations have also offered
partial insights into the mechanisms of development, and higher rate of occurrence
of both HAN and HIVAN in AAs. AAs with APOL1Vs develop idiopathic FSGS at four-
fold higher rate compared to European Americans (EAs). Similarly, HIV infected AAs with
APOL1Vs (if not on antiviral therapy), risk a 50% (10-fold greater) chance of developing
HIVAN. It has been suggested that APOL1Vs expression may render podocytes more
vulnerable to various types of injury: bacterial, viral, and others. However, in addition to
genetic variants, additional factors such as persistence of a second hit may determine the
nature and severity of glomerular disease. In patients with HAN, heroin or contaminants
may have been the offending second insult(s) which caused renal disease in susceptible
AA patients. In the 80’s, since heroin-induced second hit was neither consistent nor
sustained (depending on drug availability in the street), the disease was masked or
replaced HIV infected patients (especially in untreated subjects), by an overwhelming
second hit by the virus which was both intense as well as persistent. It appears that
APOL1Vs may be one of the links between the disappearance of HAN and emergence
of HIVAN in AA patients.
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Introduction
There has been an explosive growth in illicit drug use in general
and in the USA in particular during the last past 45 years.
Although being only 4.6% of the world’s population, Americans
consume 80% of the global opiates supply and 99% of the
global hydrocodone supply (Catalanom et al., 2011). According
to CDC, 40% of HIV-infected individuals in the United States
are associated with the use of injection drugs; similarly, among
injection drug users, 40–45% are HIV infected (CDC, 2010).
Thus, use of drugs in patients with HIV infection is an unresolved
problem of high relevance. Since factors associated with heroin
addiction such as bacterial and viral infections carry the potential
to contribute to the development of renal lesions, it is not clear
whether it is heroin or its metabolite, morphine, or associated
adulterants which are responsible for the entity morphologically
described as HAN (Kimmel and Moore, 1997; Freedman et al.,
1999; Kimmel et al., 2001; Norris et al., 2001; Satko and
Freedman, 2004).
The number of cases of “heroin nephropathy” has been
decreasing over the years, despite the increased prevalence
of heroin use. Although focal glomerulosclerosis has been a
predominant pathological feature in patients with heroin abuse
in several studies (Salomon et al., 1972; Friedman et al., 1974;
Rao et al., 1977; Friedman and Rao, 1995), but other studies have
not shown any uniform pathologic presentation (McGinn et al.,
1970; Kilcoyne et al., 1972; Grisham et al., 1976; Llach et al., 1979;
Cunningham et al., 1980, 1983; Dettmeyer et al., 1998; do Sameiro
Fario et al., 2003). It is not clear whether heroin is contributing to
renal lesions in these patients or whether nephropathy is related
to demographic, socioeconomic, or genetic factors of individual
users (Kimmel and Moore, 1997; Freedman et al., 1999; Kimmel
et al., 2001; Norris et al., 2001; Satko and Freedman, 2004).
Focal segmental glomerulosclerosis (FSGS) is the most
common type of renal lesions in AAs (Kitiyakara et al., 2003).
Genetic factors do play a role in the development of FSGS
but their role has been debated for a long time (Devarajan
and Spitzer, 2002; Tucker, 2002; Kitiyakara et al., 2003, 2004;
Kopp and Winkler, 2003; Winn, 2003; Andreoli, 2004; Orloff
et al., 2005). On that account it has been suggested that that
black heroin users with FSGS have a genetic susceptibility to the
development of renal disease, unrelated to the drug use. Thus,
it is not clear whether development of FSGS in drug users is
primarily related to genetics or to the drug use. Alternatively,
genetic may be a first hit and drug use might be the second hit.
Moreover, besides FSGS several other types of renal lesions are
associated with heroin use (McGinn et al., 1970; Kilcoyne et al.,
1972; Grisham et al., 1976; Llach et al., 1979; Cunningham et al.,
1980, 1983; Dettmeyer et al., 1998; do Sameiro Fario et al., 2003).
Heroin-associated Nephropathy (HAN)
In early 1970s, many clinicians observed excessive urinary
protein excretion and renal functional abnormalities in heroin
addicts. Rao et al. described the natural history of renal disease
in heroin addicts who presented with massive proteinuria and
focal segmental glomeulosclerosis (FSGS) which progressed to
end stage kidney disease (ESKD) in months, and coined the
term Heroin-Associated Nephropathy (HAN) (Kilcoyne et al.,
1972; Rao et al., 1974, 1977). These patients were mostly
young men predominantly of African American (AA) descent
residing in large Metropolitan areas (Kilcoyne et al., 1972;
Rao et al., 1974, 1977; Cunningham et al., 1983; Friedman,
1983; May et al., 1986). An increased risk for ESKD with an
odds ratio of 19.1 was noted for heroin users vs. non-users
(Cunningham et al., 1980). In addition to genetic predilection,
occurrence of HAN was attributed to bacterial or viral toxins
and street contaminants (Rao et al., 1977; Cunningham et al.,
1980, 1983). HAN occurrence peaked in late 70’s and early
80’s and accounted for large number of young AA men
with ESKD on maintenance dialysis (Cunningham et al.,
1983). Renal involvement in heroin addiction manifested in
multiple forms including FSGS, amyloidosis (in subcutaneous
heroin addicts), endocarditis-associated glomerulonephritis,
hepatitis-related glomerulonephritis, and acute renal failure
from rhabdomyolysis (Kilcoyne et al., 1972; Rao et al., 1977;
Cunningham et al., 1980, 1983; Friedman, 1983; Baldwin et al.,
1993; Dettmeyer et al., 1998).
Other investigators found no specific histologic or
immunofluorescence pattern in heroin users with renal disease
(Llach et al., 1979). They described a spectrum of disease pattern
including FSGS, minimal change disease, MPGN, mesangial
proliferation, dysproteinemias, and diabetic nephropathy (Llach
et al., 1979).
Unfortunately, there is no prospective controlled trial or well-
designed epidemiologic studies have been carried out to confirm
the role of heroin in the development of heroin nephropathy.
Previous studies have been conducted predominantly on
hospital-admitted patients and they may have several other
confounding factors, which might have been missed.
Opiates and Kidney Disease
Clinical studies indicated that opiate addicts are at an increased
risk for progressive chronic kidney disease (Baldwin et al., 1993;
Perneger et al., 2001). Since mesangial expansion is considered to
be a precursor of focal glomerulosclerosis, we evaluated the effect
of opiates on mesangial cell proliferation and matrix synthesis.
In vitro studies have shown that morphine (a metabolite of
heroin) directly stimulates proliferation of glomerular epithelial
cells, mesangial cells, fibroblasts, and medullary interstitial cells
(Singhal et al., 1992, 1997, 1998; Patel et al., 2003a). Morphine
at higher concentration inhibited growth of mesangial cells,
fibroblasts, and glomerular epithelial cells (Singhal et al., 1992,
1997, 1998; Patel et al., 2003a). It stimulates the production
of superoxide by macrophages and nitric oxide by mesangial
cells (Singhal et al., 1994; Kapasi et al., 2000). Morphine exerts
a bimodal effect on heme oxygenase activity in glomerular
epithelial cells, macrophages, and mesangial cells (Patel et al.,
2003b) and also promoted macrophage apoptosis through the
generation of transforming growth factor-β and reactive oxygen
species (Singhal et al., 2000). Morphine-induced macrophage
activity stimulated mesangial cell proliferation (Singhal et al.,
1996a). In vivo studies, morphine inhibited matrix proteinases
and promoted accumulation of matrix and IgG complexes
in the mesangium (Sagar et al., 1994; Singhal et al., 1996a).
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Morphine also enhanced accumulation of IgG complexes in
the mesangium of rats with anti-thymoglobulin-induced kidney
injury (Pan and Singhal, 1994; Singhal et al., 1996b); additionally,
it stimulated deposition of ferritin-antiferritin complexes in
glomerular mesangium of rats (Singhal et al., 1995). Short-term
administration of morphine invoked podocyte injury in the form
of effacement of foot processes and down regulation of nephrin
expression by podocytes (Lan et al., 2013). Morphine promoted
mesangial cell proliferation, glomerulomegaly, and proteinuria in
control as well as in sickle cell mice (Weber et al., 2008, 2012).
All these in vitro and in vivo studies suggested that morphine
has potential to cause mesangial expansion, a precursor of FSGS.
However, none of these models represent classical phenotype of
HAN.
Human Immunodeficiency Virus-associated
Nephropathy (HIVAN)
A decade after reporting HAN, Rao et al. described another
group of patients, exclusively young AAs, both heroin addicts
and non-addicts with the Acquired Immunodeficiency syndrome
(AIDS), who presented with massive proteinuria, FSGS, rapidly
progressing to ESKD (Rao et al., 1984, 1987; Rao and Friedman,
1989). Initially, this entity was referred to as AIDS associated
nephropathy, but with the identification of causative agent
Human Immunodeficiency Virus (HIV), these authors coined
the term HIVAN (Rao and Friedman, 1989). Interestingly,
an increase in the incidence of HIVAN was associated with
a dramatic decline in new cases of HAN, despite growing
number in heroin addiction population (Friedman and Rao,
1995; Monahan et al., 2001). Collapsing form of FSGS is the
renal lesion typically seen in patients with HIVAN (D’Agati et al.,
1989; Valeri et al., 1996). Numerous studies which analyzed
the risk factors for development of renal disease, have shown
that more than 90% of patients with HIV associated FSGS are
AAs (Bourgoignie et al., 1989; Halevy et al., 2001). Idiopathic
FSGS and its collapsing variants are also commonest causes of
non-diabetic renal syndromes in AAs (Valeri et al., 1996).
All these observations has led to the speculation that
genetic component is a major risk factor for development and
progression of renal disease in AAs. However, this concept was a
speculation until recent studies which focused on genetic variants
are providing valuable evidence in support of this hypothesis.
Even in the experimental models of HIVAN in transgenic
mice, susceptibility to kidney disease is influenced by HIV
genes and host genetic variants (Rappaport et al., 1994). The
initial Tg26 mouse line (model of HIVAN) was generated on
the FVB/N inbred mouse strain. This strain was susceptible
to develop renal lesions, however, Tg26 mice bred onto the
mixed FVB/CAST background mouse strain and others did not
develop renal lesions (Gharavi et al., 2004). Genome-wide linkage
analysis revealed mouse chromosome 3A1 to 3 region as an
HIVAN-susceptibility locus (Chan et al., 2009). Replacement
of the FVB/N allele in this locus by the CAST allele induced
accelerated disease progression. In addition to Tg26, several other
transgenic models have been generated to determine the role of
specific HIV genes in the pathogenesis of HIVAN. Expression
of an HIV 1gag/pol/nef transgene in mice induced FSGS
and microcystic tubular dilation but not podocyte proliferation
(Kajiyama et al., 2000); however, when this transgenic mice were
back-crossed to a Nef-only transgenic mice, the severity of renal
lesions increased (Dickie et al., 1993); these findings indicated the
role of Nef and another gene in HIVAN pathogenesis. In another
study, in Tg26 mouse model, vpr, nef, or both were additionally
deleted; only mice carrying an intact Vpr gene developed FSGS
with tubular dilation (Dickie et al., 2004). All these studies
indicate the role of specific HIV genes in the pathogenesis in
HIVAN.
Apolipprotein (APO) L1
This gene is located at chromosome 22q13.1, and encodes the
minor APOL1 component of High-Density Lipoprotein (HDL).
It is expressed in liver, pancreas, kidney, brain, macrophages,
endothelial, and several other cell types (Bergman et al., 1996;
Duchateau et al., 1997). The G1 variant (rs73885319) is a
compound missense mutation (S342G:I384M), encoding two
non-synonymous amino acids. G2 variant is a 6 bp in-frame
deletion which has resulted in the loss of two amino acids
(N388 and Y389) at the C-terminal helix of APOL1 (Dunham
et al., 1999; Genovese et al., 2013). Approximately 34% of AAs
possess one of the two risk variants and approximately 13%
have both coding variants (Dunham et al., 1999; Wasser et al.,
2012; Genovese et al., 2013). In the United States, approximately
3 million AAs carry both risk alleles. In contrast, APOL1 risk
variants occur infrequently in EAs, approximately 0.3% carry G1
and 0.1% G2 alleles.
APOL1 and Kidney Disease
AAs develop higher rates of progressive nephropathy, including
idiopathic FSGS, HIVAN, and hypertension-attributed ESKD as
compared to European Americans (EAs) (Kopp et al., 2011;
Quaggin and George, 2011; Wasser et al., 2012). This disparity
is most pronounced in patients with HIV-infection who are
not taking highly active antiretroviral drugs. The rate of the
development of HIVAN is greater than 10-fold in such untreated
subjects (US Renal Data System, 2009). This overwhelming
population disparity between AAs and EAs and, greater familial
clustering among AA, point to a prominent contribution of
underlying genetic factor(s) (Freedman et al., 1999). Recent
evidence has shown that this major health disparity is strongly
associated with two coding sequence variants (G1 and G2) in
APOL1 (Genovese et al., 2010; Tzur et al., 2010; Friedman et al.,
2011; Foster et al., 2013). In a recent study, human podocytes
expressing APOL1 variants (G1 and G2) displayed enhanced
lysosomal swelling and podocyte necrosis (Lan et al., 2014).
Moreover, even an overexpression of APOL1 wild type was
associated with podocyte toxicity. Interestingly, renal biopsy
specimens in patient with APOL1 variants smooth muscle cells
displayed enhanced APOL1 expression (Madhavan et al., 2011).
These findings prompted us to look into a possibility that smooth
muscle may be serving as an endocrine or paracrine source of
APOL1 for delivery to podocytes (Lan et al., 2015). This is a
plausible hypothesis but needs to be tested in future studies. Since
only 4% out of 13% of AAs expressing APOL1 variants develop
kidney disease, it appears that in addition to the genetic markers,
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there has to be additional insult to make podocytes vulnerable to
injury. Persistent viral load in the blood and continued exposure
to virus accounts for higher rate of HIVAN in this vulnerable
population, further supporting this notion.
Renal biopsy studies in patients with FSGS and HIVAN
revealed lower expression of APOL1 in podocytes when
compared other cells (Madhavan et al., 2011). In a recent report,
no correlation was observed between circulating APOL1 levels
with HIV infection status or inflammatory mediators in an HIV
positive cohort with kidney disease (Bruggeman et al., 2014).
Thus, at present it is not clear whether it is locally expressed
APOL1 or a burst of circulating APOL1 that contributes to
kidney injury. Since there was no relationship between severity
of HIV infection and development of kidney disease (Bruggeman
et al., 2014), we propose that APOL1- induced vulnerability to
HIV effects are more critical for the development of HIVAN
rather than the level of viral load.
Transition of HAN to HIVAN in APOL1Vs Bearing
Population
Disappearance of HAN and appearance of HIVAN in the
same population was a puzzle (Friedman and Rao, 1995;
Monahan et al., 2001). Investigators who made this observation
hypothesized that availability of contaminant-free heroin may
account for the disappearance of HAN (Friedman and Rao,
1995). In some earlier studies, Haskell et al. suggested some
relationship between HAN and HLA type (Haskell et al., 1988).
Recent observations on the role of APOL1 variants in the
development of kidney disease in AAs, it appears that heroin may
have acted as a trigger for the induction of renal injury in this
population. Nevertheless, when the same population was exposed
to a stronger and continuous trigger such as HIV infection, the
effect of an inconsistent hit such as heroin might have nullified.
Conclusions
The predominant renal lesion in heroin users is FSGS; however,
a variety of other renal lesions have also been reported. The
heterogeneity of renal lesions in heroin users points toward
the involvement of multiple factors, including social, economic,
and genetic. There is no experimental animal model for heroin
nephropathy despite multiple attempts by several investigators;
this suggests paucity of an ingredient(s) in the existing models.
Recent identification of APOL1 variants contributing to disparity
in prevalence of FSGS and HIVAN in AAs vs. Caucasians points
toward that missing ingredient in experimental animal models
(since rodents do not carry APLO1 gene). This also provides an
explanation for a decrease in occurrence of HAN with the surge
in HIVAN. However, to validate this hypothesis, use of opiates
need to be tested in APOL1 transgenic mice in future studies.
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